JenniferEng-WongMD

Oncology • Washington, DC

Assistant Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Eng-Wong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eng-Wong's full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Lombardi Cancer Center
Washington, DC 20007
Phone+1 202-444-4948

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
University of California Davis HealthResidency, Internal Medicine, 1996 - 1999
Stony Brook University Health Sciences Center School of MedicineClass of 1996

Certifications & Licensure

DC State Medical License 2000 - 2013
MD State Medical License 2010 - 2012

Clinical Trials

Raloxifene in Preventing Breast Cancer in Premenopausal Women Start of enrollment: 1998 Dec 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3

Publications & Presentations

PubMed

46 citations
Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer
Jennifer Eng-Wong, Jennifer Orzano-Birgani, Catherine Chow, David Venzon, Jianhua Yao
Cancer Epidemiology, Biomarkers & Prevention. 2008-07-01
149 citations
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-c...
Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu
European Journal of Cancer. 2018-01-01
201 citations
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective an...
Stephen J Luen, Roberto Salgado, Stephen B. Fox, Peter Savas, Jennifer Eng-Wong
The Lancet. Oncology. 2017-01-01

Authored Content

Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast CancerJanuary 2018